Clara cell secretory protein (CC-16) has anti-inflammatory properties and protective effects from oxidative stress on the respiratory tract and has been proposed as a biological marker of lung epithelial injury and pulmonary permeability. In this study, we evaluated serum CC-16 level as a biomarker relevant in the study of asthma and lung function phenotypes in adults from the Spanish branch of the population-based multicenter European Community Respiratory Health Survey.We measured CC-16 in serum samples of 859 participants (mean age 41 yrs; 51% women) of 3 Spanish ECRHS centers using an immunoassay. Current asthma, airflow limitation (AL) and lung function parameters (FEV1% and FVC% predicted and FEV1/FVC ratio) were considered. All estimates were adjusted for centre, type of sample, sex, age, smoking, pack-years, body mass index (BMI), and height. Mean serum CC-16 levels were 5.8 ± 2.9 μg/L, ranging from 0.37 to 19.7 μg/L. Serum CC-16 levels did not vary with current asthma in the total population. However, lower serum CC-16 levels were associated with current asthma among never smokers. Reduced CC-16 levels were associated with AL (OR=0.71, P=0.03) and with moderate severe COPD stages (RRR=0.52, P=0.01 vs no AL). CC-16 level increased with FEV1% predicted (beta=1.92, p<0.001) and FEV1/FVC (beta=0.84, p<0.001) and was borderline significant for FVC% predicted (beta=0.84, P=0.06).In summary, we found reduced serum CC-16 levels to be associated with airflow limitation and lower lung function in the general population after adjusting for the effects of cigarette smoking and other covariates. These data warrant evaluation of serum CC-16 level as a potential biomarker of lung function deficits and obstructive lung disease in the longitudinal setting.
|Titolo:||Serum levels of Clara cell secretory protein, asthma, and lung function in the adult general population.|
|Data di pubblicazione:||2013|
|Appare nelle tipologie:||01.01 Articolo in Rivista|